Raadysan Biotech
PrivateTotal Funding Raised
$845,000
Company Overview
Raadysan Biotech is a biotechnology company developing first-in-class therapies and companion diagnostics for Triple Negative Breast Cancer (TNBC).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts, Hardware Sales
AI Layer
Non-AI
Keywords
triple negative breast cancerTNBCsmall molecule inhibitorfirst-in-class therapycompanion diagnosticsoncology therapeuticsDNA replication targetbiotech licensingdrug discoveryin vitro diagnosticsIVDclinical-stage biotechpreclinical biotech
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Raadysan Biotech Comparables
Compare Raadysan Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Repare Therapeutics | 70% | |
| Telo Therapeutics | 66% | |
| Artios Pharma | 64% | |
Raadysan Biotech Funding Rounds
Historical fundraising activity
Raadysan Biotech Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Raadysan Biotech's valuation, stock price, and market status.
See something wrong or outdated?